Hutchison China MediTech Ltd ADR Stock
A loss of -1.720% shows a downward development for Hutchison China MediTech Ltd ADR.
Our community is currently high on Hutchison China MediTech Ltd ADR with 3 Buy predictions and 1 Sell predictions.
With a target price of 17 € there is a positive potential of 49.12% for Hutchison China MediTech Ltd ADR compared to the current price of 11.4 €.
Pros and Cons of Hutchison China MediTech Ltd ADR in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hutchison China MediTech Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hutchison China MediTech Ltd ADR | -1.720% | -4.202% | -9.524% | -25.000% | -14.925% | -10.236% | -50.435% |
| China Resources Pharmaceutical Group Ltd | -0.810% | -6.154% | -10.459% | -24.923% | -27.704% | -39.753% | 22.613% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | -5.000% | -8.800% | -17.986% | -16.176% | -50.649% | -41.538% |
| Repligen Corp. | -0.790% | -2.788% | 9.325% | -6.894% | -1.572% | -16.404% | -7.798% |
Comments
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $13.75 price target on the stock.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM) had its price target raised by analysts at Bank of America Corporation from $27.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HCM provided by MarketBeat